Durvalumab following definitive chemoradiotherapy among patients with stage III NSCLC in the Thai population: a real-world, multicenter observational study
{{output}}
Background: In locally advanced non-small cell lung cancer (LA-NSCLC), durvalumab as consolidation therapy following definitive chemoradiotherapy (CRT) was established as the standard of care. Given the heterogeneity of patients ... ...
